Evidence map›Paper›PMID 39868153›Full record

ArticlebioRxiv : the preprint server for biology2025

12-Lipoxygenase inhibition improves glucose homeostasis and obesity-associated inflammation in human gene replacement mice.

Kerim B Kaylan, Titli Nargis, Kayla Figatner, Jiayi E Wang, Sarida Pratuangtham, Advaita Chakraborty, Isabel Casimiro, Jerry L Nadler, Matthew B Boxer, David J Maloney and 3 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Kerim B KaylanDepartment of Medicine and Kovler Diabetes Center, The University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0001-7147-0614
Titli NargisDepartment of Medicine and Kovler Diabetes Center, The University of Chicago, Chicago, IL 60637, USA.
Kayla FigatnerDepartment of Medicine and Kovler Diabetes Center, The University of Chicago, Chicago, IL 60637, USA.
Jiayi E WangDepartment of Medicine and Kovler Diabetes Center, The University of Chicago, Chicago, IL 60637, USA.
Sarida PratuangthamDepartment of Medicine and Kovler Diabetes Center, The University of Chicago, Chicago, IL 60637, USA.
Advaita ChakrabortyDepartment of Medicine and Kovler Diabetes Center, The University of Chicago, Chicago, IL 60637, USA.
Isabel CasimiroDepartment of Medicine and Kovler Diabetes Center, The University of Chicago, Chicago, IL 60637, USA.
Jerry L NadlerDepartment of Pharmacology, New York Medical College, Valhalla, NY 10595, USA.
Matthew B BoxerVeralox Therapeutics, Frederick, MD 21704, USA.
David J MaloneyVeralox Therapeutics, Frederick, MD 21704, USA.
Ryan M AndersonDepartment of Medicine and Kovler Diabetes Center, The University of Chicago, Chicago, IL 60637, USA.
Raghavendra G MirmiraDepartment of Medicine and Kovler Diabetes Center, The University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0002-5013-6075
Sarah A TerseyDepartment of Medicine and Kovler Diabetes Center, The University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0003-0667-2361

Funding

Pilot and Feasibility ProgramP30DK020595 · NIDDK · UNIVERSITY OF CHICAGO · PI RONALD N COHEN · 2013 to 2026
$20.9M
INTERGRATED CLINICAL AND BASIC ENDOCRINOLOGY RESEARCHT32DK007011 · NIDDK · UNIVERSITY OF CHICAGO · PI Raghavendra G Mirmira · 1986 to 2026
$5.8M
Novel therapeutic for treatment of type 1 diabetesR41DK122917 · NIDDK · VERALOX THERAPEUTICS, INC · PI MALONEY, DAVID JOSEPH, MIRMIRA, RAGHAVENDRA G · 2020 to 2020
$300k
The 12-HETE receptor Gpr31 in the -cell pathogenesis of type 1 diabetesR03TR003381 · NCATS · UNIVERSITY OF CHICAGO · PI MIRMIRA, RAGHAVENDRA G, TERSEY, SARAH A. · 2020 to 2020
$162k
NCATS NIH HHS R03 TR003381NIDDK NIH HHS P30 DK020595NIDDK NIH HHS R41 DK122917NIDDK NIH HHS T32 DK007011
6 · The paper itself

Abstract

Obesity-associated inflammation is characterized by macrophage infiltration into peripheral tissues, contributing to the progression of prediabetes and type 2 diabetes (T2D). The enzyme 12-lipoxygenase (12-LOX) catalyzes the formation of pro-inflammatory eicosanoids and is known to promote the migration of macrophages, yet its role in obesity-associated inflammation remains incompletely understood. Furthermore, differences between mouse and human orthologs of 12-LOX have limited efforts to study existing pharmacologic inhibitors of 12-LOX. In this study, we utilized a human gene replacement mouse model in which the gene encoding mouse 12-LOX (

Indexed as

lipoxygenasemacrophagemouse modelobesitypancreatic islettype 2 diabetes

Identifiers

PMID39868153
PMCPMC11761697

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.